Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

From the World Literature

From the World Literature specialists. To help keep you up-to-date with the latest advances worldwide on all aspects of drug therapy and management of cardiovascular disorders, this section of the journal brings you information selected from the drug therapy reporting service Inpharma Weekly . The following reports are selected from the latest issues, summarizing the most important research and development news, clinical studies, treatment guidelines, pharmacoeconomic and adverse reaction news, and expert opinion pieces published across a broad range of literature sources. 1 Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected from over 1600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details. The use of tradenames, identified by [’~’] or the use of a registered ( ) or trade mark (™), is for product identification purposes only and does not imply endorsement. 140 1. Long-term, Low-intensity Warfarin Prevents 2. Thrombolytics: CPR Should Not Be Recurrent Venous Thromboembolism (VTE) a Contraindication Thrombolytic treatment should not be withheld in patients who Long-term low-intensity warfarin therapy is "a highly effective have experienced a cardiac arrest and received CPR as a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

From the World Literature

American Journal of Cardiovascular Drugs , Volume 3 (2) – Sep 20, 2012

Loading next page...
 
/lp/springer-journals/from-the-world-literature-H0156Bw4gd

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200303020-00007
pmid
14727940
Publisher site
See Article on Publisher Site

Abstract

specialists. To help keep you up-to-date with the latest advances worldwide on all aspects of drug therapy and management of cardiovascular disorders, this section of the journal brings you information selected from the drug therapy reporting service Inpharma Weekly . The following reports are selected from the latest issues, summarizing the most important research and development news, clinical studies, treatment guidelines, pharmacoeconomic and adverse reaction news, and expert opinion pieces published across a broad range of literature sources. 1 Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected from over 1600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details. The use of tradenames, identified by [’~’] or the use of a registered ( ) or trade mark (™), is for product identification purposes only and does not imply endorsement. 140 1. Long-term, Low-intensity Warfarin Prevents 2. Thrombolytics: CPR Should Not Be Recurrent Venous Thromboembolism (VTE) a Contraindication Thrombolytic treatment should not be withheld in patients who Long-term low-intensity warfarin therapy is "a highly effective have experienced a cardiac arrest and received CPR as a

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Sep 20, 2012

There are no references for this article.